30th week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210228648 | WORM PRODUCTS AND METHODS OF USE - The present invention relates to the use of a composition comprising a helminth product for prevention, treatment and/or amelioration of a clinical condition associated with the RIG-LISTING and TLR pathways. Specifically, the composition is provided for use in the treatment of clinical conditions associated with constitutive activation of type I interferon (IFN), including monogenic type I interferonopathies and inflammatory or autoimmune disorders. The present invention also relates to different methods of manufacturing a helminth product. | 2021-07-29 |
20210228649 | AMMONIA OXIDIZING MICROORGANISMS FOR THE TREATMENT OF DIAPER RASH, ATHLETE?S FOOT, CONTACT DERMATITIS, PERSPIRATION, AND BODY ODOR - A method of treating diaper rash in a subject is provided. A method of treating athlete's foot in a subject is provided. A method of treating contact dermatitis in a subject is provided. A method of treating perspiration and body odor in a subject is provided. The method comprises administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the diaper rash, athlete's foot, contact dermatitis, or perspiration and body odor. Related preparations, kits, and devices are also provided. | 2021-07-29 |
20210228650 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS - Described herein are methods and compositions for the treatment of skin conditions associated with dysbiosis. Skin conditions associated with dysbiosis for treatment using compositions and methods described herein include atopic dermatitis, eczema, dermatitis, psoriasis, rosacea, and acne. Compositions include single or more than one strain of healthy donor derived bacteria for administration to provide therapy for skin conditions associated with dysregulated microbiota. Such compositions include gram negative and/or gram positive bacteria. | 2021-07-29 |
20210228651 | LACTIC ACID BACTERIUM, BLOOD IRON INCREASING AGENT, AND ANEMIA IMPROVING AGENT - A lactic acid bacterium is provided which has high foodstuff suitability, easy to manufacture, and can increase the blood iron concentration, thereby improving anemia. A lactic acid bacterium of salt-tolerant that increases the blood iron concentration. | 2021-07-29 |
20210228652 | ANTIMICROBIAL THERAPY - Methods and compositions comprising hogocidin peptides (SH-lantibiotics), derivatives and variants are provided. Also provided are methods and compositions comprising probiotic compositions utilizing strains of | 2021-07-29 |
20210228653 | BACILLUS LICHENIFORMIS STRAIN WITH PROBIOTIC ACTIVITY - The current invention concerns a new | 2021-07-29 |
20210228654 | Methods and Systems for Assisting in Reduction of Jet Lag Symptoms in a Body - A method includes ingesting a first portion of a first supplement within three hours prior to boarding an airplane for a flight and ingesting a first portion of a second supplement alongside the first portion of the first supplement, wherein the first portion of the second supplement comprises a probiotic. The method includes ingesting a second portion of the second supplement alongside a first portion of a third supplement during the flight. The method includes ingesting a second portion of the first supplement alongside a second portion of the third supplement within three hours of the airplane landing. | 2021-07-29 |
20210228655 | ALTERING THE INTESTINAL MICROBIOME IN CYSTIC FIBROSIS - The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of | 2021-07-29 |
20210228656 | BIFIDOBACTERIUM LACTIS BL-99 AND APPLICATION THEREOF | 2021-07-29 |
20210228657 | FOOD COMPOSITION AND PHARMACEUTICAL COMPOSITION USED FOR INCREASING EXERCISE PERFORMANCE AND AMELIORATING FATIGUE - An isolated lactic acid bacteria strain: | 2021-07-29 |
20210228658 | NOVEL LACTOBACILLUS REUTERI ATG-F4 STRAIN HAVING FUNCTION OF ENHANCING DOPAMINE SECRETION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF PSYCHOPATHY | 2021-07-29 |
20210228659 | PHAGE THERAPY - The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against | 2021-07-29 |
20210228660 | USE OF PROTEASOME INHIBITOR AND ALPHAVIRUS IN PREPARATION OF ANTI-TUMOR MEDICAMENT - Use of a proteasome inhibitor and an alphavirus in the preparation of an anti-tumor medicament. The proteasome inhibitor can be used to prepare an alphavirus anti-tumor synergist. A pharmaceutical composition comprising a proteasome inhibitor and an alphavirus, including a pharmaceutical kit comprising the proteasome inhibitor and the alphavirus, and use of the proteasome inhibitor and the virus in the treatment of tumors, particularly tumors insensitive to the alphavirus. | 2021-07-29 |
20210228661 | ANTI-PARASITIC COMPOSITION - An anti-parasitic composition is provided that includes at least one seaweed material, at least one plant material, or a combination of at least one seaweed material and at least one plant material, for inhibiting, reducing, and/or suppressing growth of at least one parasite. | 2021-07-29 |
20210228662 | Plant stem cell product treatments - Embodiments of the invention include plant stem cell products and treatment devices for applying the plant stem cell products. In some embodiments, the products include extracts of plant stem cells, such as lingonberry stem cells and orchid stem cells, and an aerosolizing device configured to create an aerosol from the plant stem cell products and to deliver the aerosol to the lung via inhalation. | 2021-07-29 |
20210228663 | COMPOSITIONS COMPRISING ORGANIC MINERAL CHELATES, NIACINAMIDE, AND HEMP OIL AND USES THEREOF FOR NEUROPROTECTION, CARDIOPROTECTION, DETOXIFICATION, IMMUNE SUPPORT, AND ANTI-AGING - The compositions of this disclosure provide broad-spectrum nutrient supplementation to support the health of multiple organ and tissue systems in which mitochondrial function plays a fundamental role. In particular, the formulations promote neuroprotective, cardioprotective, immunosupportive, and anti-aging benefits. Also provided herein are novel, neuroprotective preparations containing a combination of broad- or full-spectrum hemp oil extract combined with niacinamide, a non-flushing form of vitamin B3, and methods of use are described allowing for safe, effective, and convenient use of a neuroprotective, antioxidant preparation for general and clinical use. | 2021-07-29 |
20210228664 | OKRA-DERIVED ANTIVIRAL COMPOSITION AND USES THEREOF - Artificial cervical fluid is disclosed that contains a mucilaginous extract from the okra plant. The mucilaginous extract can be produced using a hot aqueous extractant or cold extraction process followed by separation of larger particles from the extract. The extract finds many uses, for example as a sperm storage medium, a sperm freezing medium, a sexual lubricant, an artificial insemination medium, an in vitro fertilization medium, and methods for treating and/or preventing infection, replication, and transmission of viruses, such as sexually transmitted viruses. | 2021-07-29 |
20210228665 | ANTITHROMBOTIC COMPOSITION COMPRISING ANGELICA GIGAS NAKAI EXTRACT - Provided are an antithrombotic composition (platelet aggregation inhibitor) comprising an | 2021-07-29 |
20210228666 | COMPOSITION COMPRISING ASTER SPHATHULIFOLIUS MAXIM EXTRACT FOR PREVENTING, IMPROVING, OR TREATING MUSCULAR DISEASES OR FOR IMPROVING MUSCULAR FUNCTIONS - The present invention relates to a composition comprising | 2021-07-29 |
20210228667 | HEALTH-CARE PRODUCT COMPOSITION FOR ENRICHING ASTHENIC DISEASE, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention relates to a health-care product composition for enriching asthenic disease, a preparation method therefor and use thereof. According to parts by mass, the raw materials required for preparing the composition comprise: 5 to 40 parts of dandelions, 10 to 120 parts of bulbous vegetables, 10 to 100 parts of condiment leafy vegetables, and 8 to 16 parts of fruits. The method for preparing the health-care product composition for enriching asthenic disease comprises the following steps: the raw materials such as dandelion, bulbous vegetables, and condiment leafy vegetables are pulverized and mixed to obtain a solid mixture; the solid mixture is leached with purified water and filtered to obtain a leaching juice; the leaching juice is concentrated to obtain a concentrated liquid; ethanol is added to the concentrated liquid to precipitate and remove impurities so as to obtain a refining solution; the refining solution is subjected to embedding treatment so as to obtain an extracting solution; the extracting solution is lyophilized to obtain a lyophilized powder of the health-care product composition for enriching asthenic disease. The health-care product composition for enriching asthenic disease prepared by the method contain no hormones, has no obvious toxic and side effects, and has the efficacy of enriching asthenic disease, tonifying kidney and strengthening yang. | 2021-07-29 |
20210228668 | MICROVESICLES DERIVED FROM FERMENTED PLANT-BASED PRODUCTS, METHOD FOR THEIR PREPARATION AND USE - Provided are extracellular vesicles prepared from fermentation products of natural raw materials as well as methods for their production and enrichment. The extracellular vesicles are characterized by a unique size distribution and are particularly suitable for use in health-promoting products, food supplements and drugs. | 2021-07-29 |
20210228669 | A COMPOSITION COMPRISING A MIXTURE OF AN EXTRACT AND BENTONITE - A composition including a mixture of trigonella foenum-graecum extract and bentonite. The mixture is applicable in several technological fields, including the pharmacological, cosmetic, and veterinary field. Notably, the composition is useful in the treatment of a viral infection. The composition is synergistic in the sense that the mixture of trigonella foenum-graecum extract and bentonite has a higher efficiency than each of the components alone. | 2021-07-29 |
20210228670 | PHARMACEUTICAL COMPOSITION AND FUNCTIONAL HEALTH FOOD FOR PREVENTING OR TREATING MACULAR DEGENERATION - A composition according to an embodiment of the present disclosure includes a banaba leaf extract, a guava leaf extract or a mixture thereof. The composition inhibits photooxidation of A2E due to blue light, inhibits a death of retinal pigment epithelial cells induced by blue light, and inhibits a damage to outer nuclear layers of visual cells in an animal model with blue light-induced macular degeneration, and thus can be beneficially used as a composition for preventing or treating macular degeneration and as a health functional food for preventing or alleviating macular degeneration. | 2021-07-29 |
20210228671 | EXTRACT OF VEGETATION WATERS FOR USE IN THE TREATMENT AND/OR IN THE PREVENTION OF PROSTATE CANCER - The present invention relates to a natural phytocomplex or concentrate rich in polyphenolic compounds such as hydroxytyrosol and 3,4-DHPA-EDA derived from the waters from the pressing of olives for oil and/or pomace oil residues of the olive milling process, for use in the treatment and/or in the prevention of prostate carcinoma. | 2021-07-29 |
20210228672 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF - Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components. | 2021-07-29 |
20210228673 | NO (NITRIC OXIDE, ALSO CALLED NITROGEN MONOXIDE) PRODUCTION PROMOTER, ENHANCER OF INSTANTANEOUS FORCE IN MUSCLES OF LOWER EXTREMITY, AND REDUCER OF MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE - A method of promoting NO-production in a human being includes providing an extract of Kenyan purple tea (scientific name: | 2021-07-29 |
20210228674 | INCREASE IN THE CONTENT OF ESSENTIAL FATTY ACIDS IN EGGS VIA NUTRITIONAL SUPPLEMENTATION OF ANIMALS USING A VERY LOW DOSE OF A FLAVONOID-RICH GRAPE EXTRACT - Method for modifying the essential fatty acid profile of eggs through low-dose nutritional supplementation based on plant extract rich in flavonoids in the plant extract. | 2021-07-29 |
20210228675 | HYPERTROPHIC SCAR INHIBITING COMPOSITION - A composition for inhibiting the formation of hypertrophic scar, comprising at least one of a polypeptide consisting of an amino acid sequence having a dipeptide sequence represented by Pro-Hyp or Hyp-Gly, a chemically-modified form thereof, or a pharmaceutically acceptable salt thereof. | 2021-07-29 |
20210228676 | Combination Therapy With LIV1-ADC and PD-1 Antagonist - The present disclosure relates, in general, to methods for treating LIV-1-expressing cancers comprising administering an anti-LIV-1 antibody drug conjugate (LIV-1-ADC) in combination with a PD-1 antagonist, such as an anti-PD-1 antibody. | 2021-07-29 |
20210228677 | PHARMACEUTICAL COMPOSITION AND A METHOD FOR ITS MANUFACTURE - Disclosed is a storage stable pharmaceutical composition containing at least one active pharmaceutical ingredient selected from peptides of the general formula 1 [SEQ ID NO: 1-144] or peptides of the general formula 2 [SEQ ID NO: 145-288], or, their derivatives, analogs or pharmaceutically acceptable salts, or co-crystals of these peptides, their derivatives or analogues; and a pharmaceutically acceptable carrier, wherein the composition retains at least 80% of the potency of active pharmaceutical ingredient in the pharmaceutical composition after storage for at least four months at room temperature. Also, disclosed are process for their preparation and methods of use. | 2021-07-29 |
20210228678 | Method of Treatment - The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans. | 2021-07-29 |
20210228679 | PISCINE-DERIVED PYY PEPTIDES FOR USE IN TREATING A METABOLIC DISORDER - The present invention relates to peptides for use in the treatment of metabolic disorders. In particular, the present invention relates to peptides for use in the treatment of diabetes. According to the present invention, there is provided a peptide for use in the treatment of a metabolic disorder; wherein the peptide is a piscine-derived PYY or fragment or analogue thereof. | 2021-07-29 |
20210228680 | METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS - The present invention relates to the use of a CD24 protein for preventing or treating Graft versus Host Disease and mucositis. | 2021-07-29 |
20210228681 | COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA - Compositions and methods for treating malignant gliomas such as glioblastoma are provided, comprising a combination of a peptide conjugate comprising an amino acid sequence derived from the N-terminus of the receptor PAR-1, and the chemotherapeutic agent temozolomide. | 2021-07-29 |
20210228682 | METHOD FOR IDENTIFYING, EXPANDING, AND REMOVING ADULT STEM CELLS AND CANCER STEM CELLS - The invention relates to the fields of biochemistry, pharmacy and oncology. The invention particularly relates to the use of novel stem cell markers for the isolation of stem cells. The invention further relates to the obtained stem cells and their use in for example research or treatment, for example, for the preparation of a medicament for the treatment of damaged or diseased tissue. | 2021-07-29 |
20210228683 | WHEY PROTEIN CONCENTRATE IN ASSOCIATION WITH ANTITUMOUR TREATMENT - The present invention relates to highly purified whey proteins of well-defined composition for use in an anti-tumour therapy in combination with one or more anti-tumour drugs and/or radiotherapy. | 2021-07-29 |
20210228684 | SILK-BASED PRODUCT FORMULATIONS AND METHODS OF USE - Embodiments of the present disclosure include formulations of silk-based product (SBP) formulations and related methods of preparation and use in a variety of applications in the fields of human therapeutics, veterinary medicine, agriculture, and material science. | 2021-07-29 |
20210228685 | IMPROVED WEIGHT LOSS THERAPY - A pharmaceutical composition is provided comprising a first agent in an amount effective for causing both a peripheral effect and a central effect on weight loss, a second agent in an amount effective for causing at least a central effect on weight loss, and one or more pharmaceutically acceptable excipients, wherein the first agent and the second agent are different. Also provided are a method of causing weight loss and a method of preventing or treating cachexia syndrome. | 2021-07-29 |
20210228686 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION WITH INTERFERON LAMBDA - Methods of treating a hepatitis delta virus (HDV) infection in a human patient are provided. In some embodiments, the method comprising administering to the patient a therapeutically effective amount of interferon lambda for at least four weeks. | 2021-07-29 |
20210228687 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES - There is provided a method and compositions for the treatment and/or prophylaxis of psoriasis or atopic dermatitis, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of an interferon alpha subtype, wherein the interferon 3 alpha subtype is IFN-α14, HYBRID 1 or a combination of IFN-α14 and HYBRID 1. | 2021-07-29 |
20210228688 | Serum Albumin-Binding Fibronectin Type III Domains - Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications. | 2021-07-29 |
20210228689 | STUDY ON LACTOFERRIN REGULATION OF BONE FORMATION BY MEANS OF VITAMIN D RECEPTOR - A use of lactoferrin in the preparation of a food or drug, the food or drug being used for activating a VDR signaling pathway, which is used for the treatment of bone disease, bone disease comprising: osteoporosis, bone damage, loss of bone calcium, incomplete bone development and bone abnormalities. The present invention further comprises screening for drugs that are used to promote osteoblast proliferation and differentiation by using an active state of the VDR signaling pathway. | 2021-07-29 |
20210228690 | Anti-Inflammatory Peptides and Composition Comprising the Same - A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases. | 2021-07-29 |
20210228691 | Oral Care Compositions - An oral care composition, including a catalyzing enzyme and an anhydrous matrix configured to at least partially stabilize the catalyzing enzyme, wherein the anhydrous matrix includes a source of hydrogen peroxide, an acyl donor, a non-aqueous anhydrous liquid, and a surfactant mixture including sodium lauryl sulfate (SLS), Betaine, and a poloxamer. | 2021-07-29 |
20210228692 | INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES - Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs. | 2021-07-29 |
20210228693 | PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES - The present invention provides a method of treating a nucleotide repeat expansion disorder comprising delivering a pair of engineered nucleases, or genes encoding engineered nucleases, to the cells of a patient such that the two nucleases excise the nucleotide repeat responsible for the disease permanently from the genome. The invention provides a general method for treating nucleotide repeat expansion disorders and engineered nucleases suitable for practicing the method. The invention further provides vectors and techniques for delivering engineered nucleases to patient cells. | 2021-07-29 |
20210228694 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS - Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly. | 2021-07-29 |
20210228695 | PIC1 PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF DRUG-INDUCED IMMUNE HEMOLYTIC ANEMIA - Compositions and methods for treating hemolytic anemia are described. A classical complement pathway inhibitor is used to treat hemolytic anemia, for example ceftriaxone-induced complement-mediated hemolysis. A Complement Hemolysis Using Human Erythrocytes (CHUHE) assay is also described where exogenous ceftriaxone is added to a patients serum to show enhanced lysis of the patients erythrocytes in vitro. Ceftriaxone is shown to initiate classical complement pathway-mediated hemolysis by ex vivo reversal with Peptide Inhibitor of Complement C1 (PIC1). | 2021-07-29 |
20210228696 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY - The invention provides methods of using allogeneic cells in therapy by combining allogeneic cell therapy with anti-CD137 antibody drug conjugates (ADCs). Disclosed are methods of treating or preventing a host versus graft (HvG) rejection in a human subject receiving allogeneic cell therapy by administering to the human subject an anti-CD137 ADC. | 2021-07-29 |
20210228697 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2021-07-29 |
20210228698 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-07-29 |
20210228699 | COMPOSITIONS AND METHODS FOR TARGETED IMMUNOTHERAPY - The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers. | 2021-07-29 |
20210228700 | HIGH-AFFINITY ANTI-VEGF ANTIBODY - An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10 | 2021-07-29 |
20210228701 | Dimethyl Fumarate and Vaccination Regimens - Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period. | 2021-07-29 |
20210228702 | COMBINED PROPHYLACTIC AND THERAPEUTIC VACCINES - The present invention relates to an immunogenic polypeptide comprising (i) a B-cell epitope, (ii) a T-cell epitope, and (iii) a scaffold polypeptide, wherein said scaffold polypeptide is a thioredoxin polypeptide. The present invention further relates to said immunogenic polypeptide for use in medicine and for use in treating and/or preventing inappropriate proliferation of cells and/or infection with an infectious agent, preferably HPV infection, as well as to polypeptides and vectors encoding said immunogenic polypeptide. | 2021-07-29 |
20210228703 | MUTANT OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 18 - The present invention relates to a mutated HPV18 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (for example, HPV18 and HPV45, or HPV18, HPV45 and HPV59), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. | 2021-07-29 |
20210228704 | ZIKA VIRUS VACCINE - The present disclosure relates to vaccines and methods for the prevention and treatment of Zika virus infection. Particularly, the present disclosure relates to viral and DNA vaccine vectors which includes or encode for secreted immunogenic peptides of NS1 that eliciting a protective immune response and prevent Zika virus infection of a subject. | 2021-07-29 |
20210228705 | RECOMBINANT VIRUS WITH CODON-PAIR DEOPTIMIZED REGION AND USES THEREOF FOR THE TREATMENT OF CANCER - The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regions of the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or that increases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well. | 2021-07-29 |
20210228706 | IMMUNE COMPLEX - The present invention relates to immunogenic immune complexes, related compositions, and related methods. | 2021-07-29 |
20210228707 | CORONAVIRUS RNA VACCINES - The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. | 2021-07-29 |
20210228708 | CORONAVIRUS VACCINE FORMULATIONS - Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed. | 2021-07-29 |
20210228709 | CORONAVIRUS VACCINE FORMULATIONS - Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed. | 2021-07-29 |
20210228710 | MERS-CoV VACCINE WITH TRIMERIC S1-CD40L FUSION PROTEIN - An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines. | 2021-07-29 |
20210228711 | VIRAL PARTICLE - BASED VACCINE - The present invention relates to nucleic acid molecules encoding a recombinant human cytomegalovirus (HCMV) strain, dense bodies produced by said HCMV strain and preparations of said dense bodies for use in medicine, particularly as a vaccine against HCMV. | 2021-07-29 |
20210228712 | HEPATITIS B VACCINE - A hepatitis B vaccine comprising a surface antigen particle that has only hepatitis B virus L protein or a variant thereof assembling on a lipid membrane to form the particle. | 2021-07-29 |
20210228713 | TLR7 PEPTIDE CONJUGATES - The present disclosure relates to a class of pyrimidine derivative peptide conjugates having enhanced immunomodulating properties. More specifically the peptide conjugate contains a TLR7 agonist and enhances the biological effect of the peptide to which it is coupled, increasing immunogenicity, and or lowering the effective dose of the peptide. In some embodiments, the peptide is an antigen, a vaccine, a peptide-based neoantigen vaccine, or an epitope. | 2021-07-29 |
20210228714 | CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR - The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer. | 2021-07-29 |
20210228715 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER - In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function. | 2021-07-29 |
20210228716 | PEPTIDES AND ANTIBODIES FOR THE REMOVAL OF BIOFILMS - This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system. | 2021-07-29 |
20210228717 | MULTIANALYTE IMMUNOASSAY AND USES THEREOF - The present disclosure is directed to compositions (e.g., multianalyte immunoassays) for detecting multiple Zika virus antibodies in a biological sample. Also disclosed herein are methods for identifying suitable donors for preparing a Zika virus hyperimmune composition. Methods for selectively detecting Zika virus antibodies in biological samples that may contain other flavivirus antibodies are also provided. Methods of treating, preventing, or reducing the risk of a Zika virus infection are also provided. | 2021-07-29 |
20210228718 | WATER IRRADIATED WITH ELECTROMAGNETIC ENERGIES FOR USE AS A MEDICAMENT - The present invention relates to water for use as a medicament, characterized in that to the water, electromagnetic energies in the form of:
| 2021-07-29 |
20210228719 | TRIPLET-TRIPLET ENERGY TRANSFER WITH LIGHT EXCITATION AT LONG WAVELENGTHS AND METHODS THEREOF - The field of various phototriggered drug release and photoreactions, including reactions generally based on triplet-triplet energy transfer with light excitation at long wavelengths. Systems and methods for absorbing energy in a photosensitizer, and methods for making or using such systems, kits including such systems. The systems and methods comprise transferring that energy by triplet-triplet energy transfer to cleave a cleavable or other active moiety, for instance, in order to cause the release of a releasable moiety. In some cases, these may be contained within a suitable carrier material, for example, a particle or a micelle. Such systems and methods may be used in a variety of applications, including various biological or physical applications. For example, such systems and methods may be useful for delivering drugs or other releasable moieties to regions of a subject. | 2021-07-29 |
20210228720 | ABSORBENT BIOPHOTONIC FIBER SYSTEM - The present technology generally relates to an absorbent biophotonic fiber system and to articles comprising the absorbent biophotonic fiber system as well as to the potential uses thereof, such as, for example, in wound treatment. | 2021-07-29 |
20210228721 | AGGREGATION INDUCED EMISSION-BACTERIOPHAGE BIOCONJUGATES - Aggregation-induced emission-bacteriophage bioconjugate including a bacteriophage covalently bonded to at least one aggregation-induced emission luminogen via an optional linker, pharmaceutical compositions including the same, and methods of preparation and use thereof. | 2021-07-29 |
20210228722 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof, and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: | 2021-07-29 |
20210228723 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE - The present disclosure relates to compounds and methods which may be useful for modulating the expression of fxn and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus. | 2021-07-29 |
20210228724 | BIOCONJUGATES OF NEUROPEPTIDES DERIVATIVES - A bioconjugate including at least one neuropeptide covalently bond to at least one hydrocarbon compound of squalene structure. | 2021-07-29 |
20210228725 | DRUG DELIVERY - A drug delivery vehicle comprising a vesicle conjugated to one or more targeting groups, wherein the targeting groups comprise an oligosaccharide which is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of the oligosaccharide: (I) wherein R represents the point of attachment to the vesicle.10 | 2021-07-29 |
20210228726 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE - The present disclosure relates to compounds of formula (I): | 2021-07-29 |
20210228727 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS - Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections). | 2021-07-29 |
20210228728 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF - Provided is an antibody-drug conjugate (ADC) using one or more cysteine or derivatives thereof as linkers to couple one or more drugs at the limited binding sites of an antibody, making it possible to produce an ADC product with high drug payload, or to choose a drug with less toxicity, thereby obtaining an ADC product with wide therapeutic window. In addition, since a plurality of drugs may be coupled to one binding site, the ADC products obtained by the method of the present disclosure have better uniformity in the case of same DAR value. Moreover, the amount of antibody required for production may be greatly reduced, thereby lowering the cost. Compared with the antibody-drug conjugates coupled only one drug, the antibody-drug conjugates produced by the method of the present disclosure have the same inhibition or killing effect on tumor cells while using fewer drugs for coupling to the same site. | 2021-07-29 |
20210228729 | LGALS3BP ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER - The present invention relates to a special type of non-internalizing binding moiety-drug-conjugates that specifically target LGALS3BP. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to LGALS3BP, said antibody being conjugated to cytotoxic drugs. The invention also comprises methods of the treatment of LGALS3BP-expressing cancer, including administering to a patient the disclosed drug conjugates and pharmaceutical preparations. | 2021-07-29 |
20210228730 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF - Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide. | 2021-07-29 |
20210228731 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS - The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof. | 2021-07-29 |
20210228732 | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS - Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnositcs. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor. | 2021-07-29 |
20210228733 | METHODS AND COMPOSITIONS FOR THERANOSTIC NANOPARTICLES - Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed. | 2021-07-29 |
20210228734 | CONJUGATES COMPRISING A TEMPERATURE-RESPONSIVE POLYMER AND A LIGAND CAPABLE OF BINDING ERGOSTEROL - The present invention relates to polymer conjugates. More specifically, the present invention relates to polymer conjugates capable of binding to fungi, to compositions comprising these conjugates and to the use of these conjugates for detecting the presence of fungi in a sample such as, for example, a biological sample. The present invention also provides for the use of said polymer conjugates in the treatment of a fungal infection. | 2021-07-29 |
20210228735 | HYDROGEL COMPOSITIONS - The present invention relates to hydrogel compositions comprising polymer conjugates capable of selectively binding to fungi, Gram positive bacteria and/or Gram negative bacteria. The hydrogel compositions can be used for detecting the presence of fungi, Gram positive bacteria and/or Gram negative bacteria in a sample. | 2021-07-29 |
20210228736 | PATHOGEN CONTROL COMPOSITIONS AND USES THEREOF - Disclosed herein are pathogen control compositions including a plurality of plant messenger packs, (e.g., including a plant extracellular vesicle (EV), or segment, portion, or extract thereof), that are useful in methods for treating or preventing an infection in an animal and/or decreasing the fitness of pathogens (e.g., animal pathogens), or vectors thereof. | 2021-07-29 |
20210228737 | ZWITTERIONIC BIOCOMPATIBLE POLYMERS, METHODS, AND USES THEREOF - Provided herein are biocompatible polymers having a polymer backbone and one or more repeating units, and methods of making and using the same. The repeating units can each be individually selected from a zwitterionic precursor repeating unit of Formula (I). Also provided are systems for nucleic acid delivery including the biocompatible polymers, the systems having a cationic core and a polysaccharide-anionic peptide conjugate adsorbed to the cationic core. | 2021-07-29 |
20210228738 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS - Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof. | 2021-07-29 |
20210228739 | RAAV VECTORS ENCODING OF LYSOSOMAL BETA-GALACTOSIDASE (GLB1) AND CATHEPSIN A - Aspects of the disclosure relate to methods for co-administration of recombinant AAVs (rAAVs). In some embodiments, the methods comprise administering one or more rAAVs engineered to express a transgene encoding β-galactosidase (GLB1), Cathepsin A (CTSA), and/or β-galactosidase (GLB1) and Cathepsin A (CTSA). In some embodiments, the disclosure provides methods for treating lysosomal storage disorders, such as GM-1 gangliosidosis, using compositions described by the disclosure. | 2021-07-29 |
20210228740 | GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I - A suspension useful for AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDUA gene is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating MPSI and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes. | 2021-07-29 |
20210228741 | METHODS AND COMPOSITIONS TO STIMULATE RETINAL REGENERATION - Methods and compositions are provided for regeneration of retinal neurons and vision restoration after injury, disease, or loss comprising, administration of a nucleic acid sequence encoding Ascl1 and retinal reprogramming potentiating agents, including HDAC inhibitors, STAT-signaling inhibitors and microRNA manipulations in Ascl1-induced retinal regeneration. | 2021-07-29 |
20210228742 | IN VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCT - Methods, compositions, and systems for treating subject(s) in need of plasma Factor VIII, particularly a subject having preexisting anti-FVIII inhibitory antibodies, are provided. The methods involve administering to the subject a therapeutically effective amount of an inflammation suppressor, a therapeutically effective amount of a CD8+ T cell depleting agent, and a therapeutically effective amount of a composition comprising a lentiviral vector (LV) comprising an optimized FVIII expression cassette expressibly linked to a megakaryocyte-specific promoter. Such methods, compositions, and systems are useful to treat subjects with blood clotting disorder(s), such as hemophilia A. | 2021-07-29 |
20210228743 | Intrathecal Delivery of Recombinant Adeno-Associated Virus 9 - The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-os-molar contrast agent, together with a rAA9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone. | 2021-07-29 |
20210228744 | DETECTION AND TREATMENT OF CARIES AND MICROCAVITIES WITH NANOPARTICLES - Components, for example, nanoparticles for detecting and/or treating one or more active carious lesions or microcavities in teeth of a subject are provided. The component or nanoparticle may comprise a biocompatible and biodegradable polymer (e.g., a starch) bearing at least one cationic region and/or having a net positive charge and thereby capable of associating with one or more active and/or early carious lesions on a tooth in an oral cavity of a subject. The components or nanoparticles are optionally water soluble or dispersible. The components or nanoparticle also comprises an imaging agent (e.g., a fluorophore or dye) bonded to the biocompatible and biodegradable polymer. The component or nanoparticle is thus capable of indicating the presence of one or more active carious lesions when the component or nanoparticle is associated therewith. Oral care compositions comprising such compounds/nanoparticles and methods of making and using the same are also provided. | 2021-07-29 |
20210228745 | Intranasal Delivery of Fluorescent Marker - The present invention provides a method of diagnosing a CNS disorder comprising administering a fluorescent marker of retinal integrity to a subject and generating an image of the subject's eye, wherein the fluorescent marker is delivered by intranasal administration is also provided and fluorescent markers of retinal integrity for use in such methods. Also provided is a pharmaceutical composition comprising an annex in or a functional fragment or derivative thereof conjugated to a compound of 2 kDa or less, wherein the composition comprises annex in or a functional fragment or derivative thereof conjugated at a concentration of at least mg/ml. | 2021-07-29 |
20210228746 | Affinity Magnetic Particles For Imaging System - A nanoparticle construct is provided. The nanoparticle construct includes a nanoparticle defining an outer surface, a magnetic nanocrystal carried by the nanoparticle, and a coupling agent extending from the outer surface of the nanoparticle. The coupling agent is configured to couple the nanoparticle construct to a cell. | 2021-07-29 |
20210228747 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND IMAGING OF CANCER - Compositions and methods for treating, detecting, and diagnosing cancer are disclosed. | 2021-07-29 |